Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823257 | 0.87 | ALDH1A1 (0.61) | LMNAHTTALDH1A1CYP1A2KDM4E | |
| SCHEMBL29236694 | 0.86 | NPC1 (0.73) | LMNANPC1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL29236683 | 0.86 | LMNA (0.56) | LMNANPC1HTTALDH1A1KDM4E | |
| SCHEMBL6897129 | 0.86 | NR4A2 (0.54) | LMNAALDH1A1CYP1A2KDM4ESMN1; SMN2 | |
| SCHEMBL27961458 | 0.84 | ALDH1A1 (0.50) | LMNAALDH1A1CYP1A2KDM4ESMN1; SMN2 | |
| SCHEMBL570575 | 0.84 | LMNA (0.75) | LMNANPC1HTTALDH1A1CYP1A2 | |
| SCHEMBL6897135 | 0.83 | LMNA (0.45) | LMNAHTTALDH1A1CYP1A2KDM4E | |
| SCHEMBL29236859 | 0.83 | LMNA (0.64) | LMNANPC1HTTALDH1A1CYP1A2 | |
| SCHEMBL30969381 | 0.83 | LMNA (0.64) | LMNANPC1HTTALDH1A1CYP1A2 | |
| SCHEMBL29066097 | 0.81 | SMN1; SMN2 (0.71) | NPC1CYP1A2KDM4ESMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573490-B | Diaryl-2H-aziridine compounds, preparation method and application thereof | 复旦大学 | 2024-04-30 | — | — | CN | disclosed |
| EP-1326834-B1 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS | H LEE MOFFITT CANCER CT & RES (US) | 2011-06-29 | — | — | EP | disclosed |
| US-6809093-B2 | DRUG RESISTANCE THERAPY | H. LEE MOFFITT CANCER & RESEARCH INSTITUTE, INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1326834-A2 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS | The Procter & Gamble Company (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119960-A1 | Substituted piperidine amides and methods of their use | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. | 2002-08-29 | — | — | US | disclosed |
| US-20020091120-A1 | 2-substituted heterocyclic compounds for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-07-11 | — | — | US | disclosed |
| WO-2002032868-A2 | 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE IN TREATING MULTIDRUG RESISTANCE | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119960-A1 | Substituted piperidine amides and methods of their use | ABCC1, SLC11A2, ABCB1 | LMNA 2336/4885NPC1 73/4885HTT 3504/4885 |
| US-20020091120-A1 | 2-substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | LMNA 3316/4885NPC1 35/4885HTT 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.